NACDS Welcomes FDA’s Action on Pharmacist-Prescribed COVID-19 Antivirals; Urges Next Steps for Lawmakers, CMS and Commercial Payers to Make Better Access a Reality
NACDS today welcomed the announcement by the U.S. Food and Drug Administration (FDA) that it revised the Emergency Use Authorization (EUA) for Paxlovid (nirmatrelvir and ritonavir), “to authorize state-licensed pharmacists to prescribe Paxlovid to eligible patients, with certain limitations to ensure appropriate patient assessment and prescribing of Paxlovid.”
